Breaking Finance News

RBC Capital Markets disclosed Immune Design (NDAQ:IMDZ), boosting its price target to $20.00 earlier today

Having a price of $9.38, Immune Design (NDAQ:IMDZ) traded -4.30% lower on the day. With the last stock price up 13.06% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. IMDZ has recorded a 50-day average of $9.76 and a two hundred day average of $7.87. Trade Volume was down over the average, with 127,340 shares of IMDZ changing hands under the typical 194,689

Reporting a potential upside of 1.13%, RBC Capital Markets upped the price target of Immune Design (NDAQ:IMDZ) to $20.00

On Thursday June 29, 2017, Jefferies & Co released a statement about Immune Design (NDAQ:IMDZ) upped the target price from $0.00 to $18.00 that suggested an upside of 0.94%.

Performance Chart

Immune Design (NDAQ:IMDZ)

With a total market value of $0, Immune Design has with a one year low of $4.50 and a one year high of $13.05 .

Brief Synopsis About Immune Design (NDAQ:IMDZ)

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.